Activated Charcoal in Dextromethorphan Ingestion
Activated charcoal can be administered to asymptomatic patients within 1 hour of dextromethorphan ingestion, but should only be given by healthcare professionals in a medical facility—do not administer at home or delay transport to give it. 1
Key Recommendations
The 2007 evidence-based consensus guideline for dextromethorphan poisoning provides clear direction 1:
- Do not use activated charcoal at home
- Activated charcoal can be administered to asymptomatic patients who have ingested overdoses within the preceding hour
- Administration should only be carried out by health professionals and only if no contraindications are present
- Do not delay transportation to administer activated charcoal
This aligns with the broader 2026 Clinical Toxicology Recommendations Collaborative guidance, which does not specifically list dextromethorphan among the 43 poisons evaluated for activated charcoal use 2. The absence from this comprehensive review suggests dextromethorphan is not considered a high-priority indication for activated charcoal.
Clinical Decision Algorithm
Within 1 hour of ingestion:
- If patient is asymptomatic and in a healthcare facility → Activated charcoal is reasonable if no contraindications exist
- If patient is at home → Do NOT give activated charcoal; refer to emergency department based on dose/symptoms
Beyond 1 hour post-ingestion:
- Activated charcoal has no established role
Contraindications to consider:
- Altered mental status or decreased level of consciousness
- Unprotected airway
- Risk of aspiration
- Gastrointestinal pathology
Dose-Based Referral Criteria
The guideline provides specific thresholds for emergency department referral 1:
- >7.5 mg/kg ingested → Refer to emergency department immediately
- 5-7.5 mg/kg ingested → Poison center follow-up every 2 hours for 4 hours; refer if symptoms develop
- <5 mg/kg and asymptomatic at 4 hours → Can observe at home
Important Caveats
The primary focus should be on appropriate triage and supportive care rather than gastrointestinal decontamination. Dextromethorphan toxicity manifests as CNS effects (sedation, agitation, hallucinations), serotonin syndrome (especially with SSRIs or MAOIs), and respiratory depression 1.
For symptomatic patients, naloxone can be considered for respiratory depression, and benzodiazepines are appropriate for seizures or hyperthermia from serotonin syndrome 1. These interventions take priority over activated charcoal administration.
Never perform endotracheal intubation solely to administer activated charcoal in dextromethorphan ingestion, as the risks of intubation (hypotension 1.5-11.8%, desaturation 3.4-7.1%, cardiac arrest 0.4%) likely outweigh benefits 2.